Phase I study of single-agent pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, in patients with ErbB2+metastatic breast cancer

被引：1
|
作者：
Xu, B.
Ma, F.
Chen, S.
Li, Q.
Yang, F.
Zhang, Y.
Chen, X.
Zhong, D.
Zhang, G.
机构：
[1] Chinese Acad Med Sci, Canc Hosp, Beijing 100730, Peoples R China
[2] Chinese Acad Sci, Inst Mat Med, Shanghai, Peoples R China
[3] Jiangsu Hengrui Med Co LTD, Shanghai, Peoples R China
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-P4-14-18
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-14-18
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Neratinib, an irreversible pan-ErbB receptor inhibitor, is highly effective against primary cervical cancer cell lines harboring HER2/neu gene mutations
    Lopez, S.
    Bellone, S.
    Black, J. D.
    Schwab, C. L.
    English, D. P.
    Terranova, C.
    Schwartz, P. E.
    Rutherford, T. J.
    Angioli, R.
    Santin, A.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 144 - 144
  • [32] Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2+breast cancer
    H Cortés-Funes
    C Mendiola
    L Manso
    E Ciruelos
    Breast Cancer Research, 11
  • [33] Increased bioavailability of intravenous versus oral Cl-1033, a pan erbB tyrosine kinase inhibitor: Results of a phase I pharmacokinetic study
    Simon, George R.
    Garrett, Christopher R.
    Olson, Stephen C.
    Langevin, Michael
    Eiseman, Irene A.
    Mahany, John J.
    Williams, Charles C.
    Lush, Richard
    Daud, Adil
    Munster, Pamela
    Chiappori, Alberto
    Fishman, Mayer
    Bepler, Gerold
    Lenehan, Peter F.
    Sullivan, Daniel M.
    CLINICAL CANCER RESEARCH, 2006, 12 (15) : 4645 - 4651
  • [34] A double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor
    Richat Abbas
    Bruce A. Hug
    Cathie Leister
    Daryl Sonnichsen
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 191 - 199
  • [35] A double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor
    Abbas, Richat
    Hug, Bruce A.
    Leister, Cathie
    Sonnichsen, Daryl
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (01) : 191 - 199
  • [36] PHASE I TRIAL OF IRREVERSIBLE PAN-ERBB INHIBITOR DACOMITINIB (DAC) IN COMBINATION WITH ALK/MET INHIBITOR CRIZOTINIB (CRIZ) IN PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Janne, P. A.
    Shaw, A. T.
    Giaccone, G.
    Camidge, D. R.
    Shreeve, S. M.
    Goldberg, Z.
    Tang, Y.
    Solomon, B.
    ANNALS OF ONCOLOGY, 2012, 23 : 423 - 423
  • [37] Targeting ErbB receptor interactions: A phase I trial of trastuzumab and erlotinib in metastatic HER2+breast cancer
    Britten, CD
    Pegram, M
    Rosen, P
    Finn, RS
    Wax, A
    Bosserman, L
    Gordon, L
    Lin, LS
    Mass, R
    Slamon, DJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 206S - 206S
  • [38] A CLINICAL STUDY TO ASSESS EFFECT OF RIFAMPIN ON THE PHARMACOKINETICS (PK) OF NERATINIB (HKI-272), A PAN-ERBB RECEPTOR TYROSINE KINASE INHIBITOR, WHEN ADMINISTERED CONCOMITANTLY IN HEALTHY SUBJECTS.
    Abbas, R.
    Hug, B.
    Leister, C.
    Sonnichsen, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S41 - S42
  • [39] A phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, in recurrent GBM patients.
    Reardon, D
    Cloughesy, T
    Conrad, C
    Prados, M
    Xia, J
    Mietlowski, W
    Dugan, M
    Mischel, P
    Friedman, H
    Yung, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 207S - 207S
  • [40] Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer
    Li, Xin
    Yang, Changyong
    Wan, Hong
    Zhang, Ge
    Feng, Jun
    Zhang, Lei
    Chen, Xiaoyan
    Zhong, Dafang
    Lou, Liguang
    Tao, Weikang
    Zhang, Lianshan
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 110 : 51 - 61
12345